Cryoport, Inc.
CYRX Nasdaq· Pharmaceutical Preparations
Last close · Oct 27, 2026
$18.41
KIRA · Stoqly’s AI analyst, in plain words
- Cryoport, Inc. had $176M of revenue in fiscal 2025, up 12.4% on the year before. Over five years, revenue changed +17.5% a year on average.
- Its operating margin was −20.9%, up 56.7 pts: of every 100 in sales, about −21 is left after running the business.
- Cryoport, Inc. made $78.3M of net profit in fiscal 2025.
- Free cash flow was −$25.0M in fiscal 2025, −14.2% of revenue.
- Cryoport, Inc. returned $10.0M to shareholders in fiscal 2025. The diluted share count rose 1.5%.
Market cap
$929M
P/E
—
Revenue
$176M
Net income
$78.3M
Free cash flow
−$25.0M
Operating margin
−20.9%
Cryoport, Inc. in 30 seconds · fiscal 2025
Are sales growing?
+12.4%
Yes. Sales grew 12.4% last year.
Does it make a profit?
44.4%
Yes. It keeps 44.4% of every sale as profit.
Does profit turn into cash?
−14.2%
No. It spent more cash than it brought in.
How healthy are the accounts?
4 / 8
Mixed. It passes 4 of 8 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Cryoport, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 5, 2026
- Legal name
- Cryoport, Inc.
- CIK
- 0001124524
Cryoport, Inc. · CYRX
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $223M | $237M | $169M | $157M | $176M |
| Revenue growth | 182.9% | 6.6% | −28.9% | −7.1% | 12.4% |
| Gross margin | 43.4% | 43.8% | 44.7% | 44.4% | 47.1% |
| Operating margin | −8.0% | −13.4% | −59.6% | −77.6% | −20.9% |
| Net income | −$276M | −$37.3M | −$99.6M | −$115M | $78.3M |
| Net margin | −123.8% | −15.7% | −59.0% | −73.2% | 44.4% |
| Diluted EPS | −$6.18 | −$0.93 | −$2.21 | −$2.49 | $1.40 |
| Cash | |||||
| Cash from operations | $8.1M | −$1.9M | −$0.8M | −$16.3M | −$8.6M |
| Capital expenditure | $23.9M | $22.1M | $38.8M | $17.3M | $16.4M |
| Free cash flow | −$15.8M | −$24.0M | −$39.5M | −$33.6M | −$25.0M |
| FCF margin | −7.1% | −10.1% | −23.4% | −21.4% | −14.2% |
| Share buybacks | $0.0M | $38.0M | — | — | $10.0M |
| Share count change | 19.0% | 6.7% | −0.5% | 1.3% | 1.5% |
| Debt and strength | |||||
| Cash and short-term investments | $629M | $516M | $446M | $251M | $411M |
| Shareholders' equity | $642M | $556M | $489M | $402M | $503M |
| Current ratio | 16.3x | 14.8x | 11.7x | 5.3x | 2.2x |
| Interest coverage | −3.8x | −5.2x | −18.3x | −30.6x | −15.6x |
| Returns and quality | |||||
| Return on equity | −53.8% | −6.2% | −19.1% | −25.8% | 17.3% |
| Return on tangible equity | −96.7% | −21.2% | −49.3% | −52.6% | 20.5% |
| Piotroski F-score | 4 | 4 | 3 | 2 | 4 |
| Altman Z'' | 3.8 | 2.9 | 1.6 | −0.7 | 1.0 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$4.6M
5 insiders
Of sales under plans
9%
$0.4M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Cryoport, Inc. · CYRX
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $18.41 a share, the company is worth $929M.
Source: SEC EDGAR XBRL filings (CIK 0001124524). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.